Can electroconvulsive therapy be administered to a 57‑year‑old woman with a left ventricular ejection fraction of 20%?

ECT Can Be Administered to This Patient With Severe Heart Failure, But Requires Intensive Multidisciplinary Cardiovascular Monitoring and Prophylactic Management

ECT is feasible and can be performed safely in a 57-year-old woman with an ejection fraction of 20%, provided there is close collaboration between psychiatry, anesthesiology, and cardiology with specific cardiovascular precautions in place. This represents severe systolic heart failure, but is not an absolute contraindication to ECT.

Evidence Supporting Safety in Severe Heart Failure

The most compelling evidence comes from a retrospective study of 35 patients with heart failure and reduced ejection fraction who underwent ECT 1. In this cohort:

• Median ejection fraction was 30% (range 15-40%) - notably, some patients had EF as low as 15%, even more severe than your patient
• 513 ECT sessions were completed without any deaths, decompensated heart failure, myocardial ischemia, or myocardial infarction
• Median age was 77 years (range 54-92), demonstrating safety even in elderly patients with severe cardiac dysfunction

This study provides direct evidence that ECT can be administered safely to patients with EF of 20% or lower.

Critical Cardiovascular Management Requirements

Prophylactic Beta-Blockade

Prophylactic intravenous beta-blockers should be administered before ECT to prevent the marked hypertension and tachycardia that occurs during treatment 1. In the Mayo Clinic series, this prophylaxis was used in 80% of all ECT sessions, particularly for patients who developed:

• Systolic blood pressure >180-200 mmHg during previous sessions
• Heart rate >100 bpm

Anesthesia Considerations

Standard anesthesia protocols apply, but with heightened cardiovascular monitoring 2:

• Atropine or glycopyrrolate should be administered to prevent vagally-induced bradycardia and arrhythmias
• Methohexital remains the standard anesthetic agent
• 100% oxygen ventilation before electrical stimulus
• Continuous hemodynamic monitoring throughout

Multidisciplinary Team Requirements

The treatment team must include 2:

• Psychiatrist experienced in ECT
• Anesthesiologist with cardiac experience
• Cardiology consultation for pre-ECT optimization and monitoring protocols
• Nursing staff trained in ECT and cardiac monitoring
• Designated recovery area with cardiac monitoring capabilities

Specific Cardiac Risks to Monitor

Arrhythmias

In the Mayo Clinic series, only 3 of 35 patients (8.6%) experienced temporary, non-life-threatening cardiac arrhythmias 1. However, continuous cardiac monitoring is essential as ECT causes:

• Acute catecholamine surge
• Initial parasympathetic discharge (bradycardia risk)
• Subsequent sympathetic surge (tachycardia and hypertension)

Takotsubo Cardiomyopathy

Recent case reports 3, 4 describe ECT-triggered Takotsubo cardiomyopathy, particularly in postmenopausal women with cardiovascular risk factors. Your 57-year-old female patient fits this demographic. Monitor for:

• Chest pain after ECT
• New ECG changes (ST elevation, QRS widening)
• Acute worsening of ventricular function

This complication is rare but reversible with supportive care, and does not represent an absolute contraindication to future ECT 4.

Treatment Protocol Recommendations

Pre-ECT Evaluation

• Cardiology clearance with optimization of heart failure medications
• Baseline ECG and recent echocardiogram
• Assessment of volume status and diuretic management
• Discussion of prophylactic beta-blocker protocol

During ECT

• Inpatient setting mandatory 2
• Prophylactic IV beta-blocker before each session
• Continuous cardiac monitoring (ECG, blood pressure, oxygen saturation)
• Consider starting with unilateral electrode placement to minimize cognitive side effects 2
• Brief pulse stimulation at adequate dose

Post-ECT Monitoring

• Recovery in designated area with cardiac monitoring for 1-2 hours 2
• 24-48 hour monitoring for tardive seizures 2
• Serial vital signs and assessment for chest pain or dyspnea
• Evaluation for signs of decompensated heart failure

Frequency and Course

• Begin with twice-weekly treatments rather than three times weekly to allow cardiovascular recovery between sessions 2
• Typical course of 10-12 treatments, with response assessment after 5-6 treatments 2
• Can adjust frequency based on cardiovascular tolerance

Key Caveats

This is not a contraindication, but requires significantly more intensive monitoring than standard ECT. The literature consistently demonstrates that ECT can be performed safely in severe heart failure 1, 5, including in patients with even lower ejection fractions than 20%. However, the risk-benefit calculation depends on:

• Severity of psychiatric illness (treatment-resistant depression, catatonia, severe suicidality warrant higher risk tolerance)
• Availability of experienced multidisciplinary team
• Cardiac stability (decompensated heart failure should be optimized first)
• Patient's overall medical status and life expectancy

The general principle from the literature is clear: "ECT can be performed safely in most patients with underlying cardiac conditions, as long as appropriate precautions are taken to identify these patients ahead of time" 5.